FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

					or	Sect	tion 30(h)	of the	Investme	nt Co	mpany Act	of 1940							
1. Name and Address of Reporting Person* Baity Glenn					2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS INC</u> [ACAD]								(Che	5. Relationship of Repor (Check all applicable) Director X Officer (give titl			10% Ow Other (s	ner	
(Last) (First) (Middle) 3611 VALLEY CENTRE DRIVE, SUITE 300					3. Date of Earliest Transaction (Month/Day/Year) 03/15/2016								- A below) below) EVP AND GC						
(Street) SAN DII (City)		A State)		4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable le) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
	(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
Date				ransaction e onth/Day/Year)		2A. Deemed Execution Date if any (Month/Day/Yea		e, Transaction Dispo Code (Instr.			ecurities Acquired (A) bosed Of (D) (Instr. 3, 4			5. Amoun Securities Beneficia Owned Fo Reported	es Fo ally (D) Following (I)		: Direct I Indirect E str. 4)	7. Nature of ndirect Beneficial Dwnership Instr. 4)	
								Code	v	Amount	Amount (A) or P		Price	Transacti (Instr. 3 a	ction(s)			iiisti. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Yea			Execution Date, if any		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Co	de \	v	(A)	(D)	Date Exercisat		Expiration Date	Title	or Nur	iount mber Shares		(Instr. 4)	5		
Stock Option (right to buy)	\$19.65	03/15/2016		А			150,000		(1)	•	03/14/2026	Commor Stock	15	0,000	\$0	150,0	00	D	

Explanation of Responses:

1. 25% of the shares subject to the Stock Option vest and become exercisable on March 15, 2017. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

/s/ Elizabeth Carter, Attorney-03/17/2016 in-Fact

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.